Extranodal Natural-killer/t-cell Lymphoma, Nasal Type

Overview

Journal Adv Hematol

Publisher Wiley

Specialty Hematology

Date 2011 Jan 15

PMID 21234094

Citations 35

Authors

Harinder Gill

Raymond H S Liang

Eric Tse

Affiliations

Soon will be listed here.

Abstract

The World Health Organization (WHO) classification recognizes 2 main categories of natural killer (NK) cell-derived neoplasms, namely, extranodal NK/T-cell lymphoma, nasal type, and aggressive NK-cell leukaemia. Extranodal nasal NK/T-cell lymphoma is more frequent in the Far East and Latin America. Histopathological and immunophenotypical hallmarks include angiocentricity, angiodestruction, expression of cytoplasmic CD3 epsilon (ε), CD56, and cytotoxic molecules and evidence of Epstein-Barr virus (EBV) infection. Early stage disease, in particular for localized lesion in the nasal region, is treated with chemotherapy and involved-field radiotherapy. On the other hand, multiagent chemotherapy is the mainstay of treatment for advanced or disseminated disease. L-asparaginase-containing regimens have shown promise in treating this condition. The role of autologous hematopoietic stem cell transplantation is yet to be clearly defined. Allogeneic hematopoietic stem cell transplantation, with the putative graft-versus-lymphoma effect, offers a potentially curative option in patients with advanced disease.

Citing Articles

A Case of Nasal NK T-Cell Lymphoma Presenting With Persistent Epiphora.

Yun Y, Kim Y, Pak M, Kim S J Rhinol. 2024; 29(3):176-181.

PMID: 39664303 PMC: 11524375. DOI: 10.18787/jr.2022.00415.

A Rare Case of Aggressive Disseminated Nasal-Type Epstein-Barr Virus-Positive Extranodal Natural Killer/T-Cell Lymphoma with Bone Marrow Involvement.

Yee A, Karim F, Giashuddin S, Grutman G Am J Case Rep. 2023; 24:e939286.

PMID: 37384825 PMC: 10286649. DOI: 10.12659/AJCR.939286.

Sinonasal lymphoma: A primer for otolaryngologists.

Bitner B, Htun N, Wang B, Brem E, Kuan E Laryngoscope Investig Otolaryngol. 2022; 7(6):1712-1724.

PMID: 36544932 PMC: 9764779. DOI: 10.1002/lio2.941.

Cutaneous Involvement of Extranodal NK/T Cell Lymphoma, Nasal Type, a Clinical and Histopathological Mimicker of Various Skin Diseases.

Ngamdamrongkiat P, Sukpanichnant S, Chairatchaneeboon M, Khuhapinant A, Sitthinamsuwan P Dermatopathology (Basel). 2022; 9(3):307-320.

PMID: 36135102 PMC: 9497790. DOI: 10.3390/dermatopathology9030037.

Aggressive natural killer cell leukemia with skin manifestation associated with hemophagocytic lymphohistiocytosis: A case report.

Peng X, Zhang L, Li L, Guo X, Liu Y World J Clin Cases. 2022; 9(34):10708-10714.

PMID: 35005005 PMC: 8686140. DOI: 10.12998/wjcc.v9.i34.10708.

References

Cheung M, Chan J, Lau W, Ngan R, Foo W . Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002; 54(1):182-90. DOI: 10.1016/s0360-3016(02)02916-4. View

Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y . Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009; 27(33):5594-600. DOI: 10.1200/JCO.2009.23.8295. View

Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H . Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2009; 21(5):1032-40. DOI: 10.1093/annonc/mdp418. View

Yokoyama H, Yamamoto J, Tohmiya Y, Yamada M, Ohguchi H, Ohnishi Y . Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type. Leuk Lymphoma. 2010; 51(8):1509-12. DOI: 10.3109/10428194.2010.487958. View

Lee J, Au W, Park M, Suzumiya J, Nakamura S, Kameoka J . Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant. 2008; 14(12):1356-64. DOI: 10.1016/j.bbmt.2008.09.014. View

Ooi G, Chim C, Liang R, Tsang K, Kwong Y . Nasal T-cell/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity. AJR Am J Roentgenol. 2000; 174(4):1141-5. DOI: 10.2214/ajr.174.4.1741141. View

Robbins K, Fuller L, Vlasak M, Osborne B, JING B, Velasquez W . Primary lymphomas of the nasal cavity and paranasal sinuses. Cancer. 1985; 56(4):814-9. DOI: 10.1002/1097-0142(19850815)56:4<814::aid-cncr2820560419>3.0.co;2-p. View

Lee J, Suh C, Park Y, Ko Y, Bang S, Lee J . Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2005; 24(4):612-8. DOI: 10.1200/JCO.2005.04.1384. View

Ando J, Sugimoto K, Ando M, Isobe Y, Sasaki M, Oshimi K . CD20-positive extranodal NK-cell lymphoma, nasal-type. Eur J Haematol. 2008; 80(6):549-50. DOI: 10.1111/j.1600-0609.2008.01058.x. View

10.

Kim S, Kim K, Kim B, Kim C, Suh C, Huh J . Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009; 27(35):6027-32. DOI: 10.1200/JCO.2009.23.8592. View

11.

Gill H, Lau W, Chan A, Leung R, Khong P, Leung A . CD20 expression in natural killer T cell lymphoma. Histopathology. 2010; 57(1):157-9. DOI: 10.1111/j.1365-2559.2010.03584.x. View

12.

Au W, Kim S, Yiu H, Ngan R, Loong F, Kim W . Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10-29 years after initial remission. Am J Hematol. 2010; 85(5):362-3. DOI: 10.1002/ajh.21663. View

13.

Kwong Y . High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant. 2009; 44(11):709-14. DOI: 10.1038/bmt.2009.239. View

14.

Quintanilla-Martinez L, Kremer M, Keller G, Nathrath M, Gamboa-Dominguez A, Meneses A . p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am J Pathol. 2001; 159(6):2095-105. PMC: 1850589. DOI: 10.1016/S0002-9440(10)63061-1. View

15.

Kwong Y . Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005; 19(12):2186-94. DOI: 10.1038/sj.leu.2403955. View

16.

Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T . Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995; 76(11):2351-6. DOI: 10.1002/1097-0142(19951201)76:11<2351::aid-cncr2820761125>3.0.co;2-1. View

17.

Chan W, Au W, Wong C, Liang R, Leung A, Kwong Y . Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl Med. 2010; 35(8):571-5. DOI: 10.1097/RLU.0b013e3181e4dcbf. View

18.

Gelb A, van de Rijn M, Regula Jr D, Cornbleet J, Kamel O, Horoupian D . Epstein-Barr virus-associated natural killer-large granular lymphocyte leukemia. Hum Pathol. 1994; 25(9):953-60. DOI: 10.1016/0046-8177(94)90018-3. View

19.

Au W, Pang A, Choy C, Chim C, Kwong Y . Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004; 104(1):243-9. DOI: 10.1182/blood-2003-12-4197. View

20.

Hasserjian R, Lee Harris N . NK-cell lymphomas and leukemias: a spectrum of tumors with variable manifestations and immunophenotype. Am J Clin Pathol. 2007; 127(6):860-8. DOI: 10.1309/2F39NX1AL3L54WU8. View